Testing selumetinib for adults and children with NF2-related schwannomatosis
Original title: Selumetinib for NF2-Related Schwannomatosis
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drug is still being tested in people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing a drug called selumetinib in people with NF2-related schwannomatosis.
Who this trial is for. This trial is for adults and children with neurofibromatosis type 2-related schwannomatosis, also called NF2-SWN, whose tumors cannot be removed with surgery or are growing. It is testing a drug called selumetinib.
Where it stands. The trial is looking at how well selumetinib works and how safe it is. Those answers are not in yet. This trial has not reported results.
What this means, and what it doesn't
What it could mean: If this sounds like your situation, or your child's, it is one study worth knowing about. You can ask your care team about it. They can help you think it through.
What it doesn't mean: This does not mean selumetinib is known to help. A trial is a test, not a proven treatment. Joining one is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, July 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.